HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Liraglutide.

Abstract
In January 2010, liraglutide (Victoza; Novo Nordisk)--an injectable glucagon-like peptide 1 receptor agonist--was approved by the US FDA to improve glycaemic control in adults with type 2 diabetes mellitus.
AuthorsDaniel J Drucker, Argyris Dritselis, Peter Kirkpatrick
JournalNature reviews. Drug discovery (Nat Rev Drug Discov) Vol. 9 Issue 4 Pg. 267-8 (Apr 2010) ISSN: 1474-1784 [Electronic] England
PMID20357801 (Publication Type: Journal Article)
Chemical References
  • Hypoglycemic Agents
  • Liraglutide
  • Glucagon-Like Peptide 1
Topics
  • Adult
  • Diabetes Mellitus, Type 2 (drug therapy)
  • Drug Approval
  • Glucagon-Like Peptide 1 (analogs & derivatives, pharmacology, therapeutic use)
  • Humans
  • Hypoglycemic Agents (pharmacology, therapeutic use)
  • Liraglutide
  • Randomized Controlled Trials as Topic
  • United States
  • United States Food and Drug Administration

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: